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Abstract
The goal of this study was to examine the use of
diffusion-weighted magnetic resonance imaging
(DW-MRI) for the assessment of early progression of
photodamage induced by Pd-bacteriopheophorbide
(TOOKAD)–based photodynamic therapy (PDT).
TOOKAD is a novel second-generation photosensitizer
for PDT of solid tumors developed in our laboratory
and presently under clinical trials for prostate cancer
(PC) therapy. Using the subcutaneous human prostate
adenocarcinoma WISH-PC14 xenografts in nude mice
as a model, a unique biphasic change in the apparent
diffusion coefficient (ADC) was observed within the
first 24 hours post-PDT, with initial decrease followed
by an increase in ADC. Using DW-MRI, this phenom-
enon enables the detection of successful tumor
response to PDT within 7 hours posttreatment. This
process was validated by direct, histological, and
immunohistochemical examinations and also by eval-
uation of serum prostate-specific antigen (PSA) levels
that decreased significantly already 7 hours posttreat-
ment. In vitro studies of multicellular cell spheroids
confirmed a PDT-induced decrease in ADC, suggest-
ing that lipid peroxidation (LPO) significantly contrib-
utes to ADC decline observed after PDT. These results
demonstrate that TOOKAD-based PDT successfully
eradicates prostate adenocarcinoma xenografts and
suggests DW-MRI to be useful for the detection of
early tumor response and treatment outcome in the
clinical setting.
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Introduction
Photodynamic therapy (PDT) of tumors [1] with Pd-
bacteriopheophorbide (TOOKAD) [2,3] relies on in situ
photosensitization of the circulating sensitizer with con-
sequent generation of cytotoxic reactive oxygen species
(ROS) [4]. Local ROS generation in the treated tumor
induces rapid vascular occlusion and hypoxia and initiates
lipid peroxidation (LPO) primarily in the tumor vasculature,
spreading throughout the tumor within hours after treatment
[5–8]. Overall cytotoxicity of PDT results in cell death and
necrosis of tumor components with minimal damage to the
surrounding tissues [9,10]. We previously demonstrated that
this treatment modality induces significant cure rates of
different xenograft models in mice [3,5–7,11] and in rats
[12]. Prostate cancer (PC) is the most commonly diag-
nosed noncutaneous malignancy and is the second leading
cause of cancer-related death in American men [13].
Moreover, PC is the cause of substantial morbidity and
serious complications from both local tumor and distant
metastases.
We previously showed that TOOKAD-PDT is a feasible,
efficient, and well-tolerated approach for minimally invasive
treatment of local and disseminated human small cell carci-
noma of the prostate (SCCP) and bone lesions model in mice
[6]. Furthermore, TOOKAD-PDT was recently suggested as
an alternative for PC treatment as it induces lesions in a
canine prostate model, with no evidence of urinary side effects
or nearby tissue damage [14]. Phase I/II clinical trials of
TOOKAD-PDT on patients with recurrent PC following failed
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external beam radiation therapy are presently underway in
Canada [15].
Tumor response to chemotherapy and radiotherapy is
commonly assessed by radiographic changes in tumor
morphology or, in the case of PC, often relies on serum
levels of prostate-specific antigen (PSA) [13] requiring time
elapses of weeks to months posttreatment in both cases.
Because TOOKAD-PDT is a single-session treatment mo-
dality performed within an hour or so, rapid assessment of
response to therapy will be an attractive virtue of this
minimally invasive treatment, allowing immediate patient
reprognostification and early consideration of adjuvant
treatment.
Magnetic resonance can noninvasively provide awealth of
information regarding tumor morphology, metabolism, and
pathology, thereby allowing the assessment of the response
to treatment by changes induced on these parameters.
Several magnetic resonance imaging (MRI) techniques have
been employed for the detection of response to therapy in
various types of cancer in both clinical and preclinical models.
Among the examples are T2-weighted imaging [16],
T1-weighted imaging [17], and dynamic contrast-enhanced
imaging [11,18]. Displacement of water molecules has be-
come a major intrinsic MRI contrast tool, providing the sharp-
est discrimination between healthy and malignant (prostatic)
tissues [19,20]. As such, diffusion-weighted magnetic reso-
nance imaging (DW-MRI) is also a powerful tool for the
assessment of damage induced in tumors by cytotoxic ther-
apies when changes in cell vitality are often associated with
significant changes in water diffusion. In preclinical models,
DW-MRI was shown to be a reliable tool for the detection of
tumor response to chemotherapy, irradiation, and gene ther-
apy, relatively early in the treatment regimen [19]. We there-
fore examined the possibility to assess treatment response by
applying DW-MRI for rapid monitoring of PC response to
TOOKAD-PDT. Although the exact mechanisms underlying
changes in apparent diffusion coefficient (ADC) following
therapy are unascertained, it is commonly hypothesized that
the increased ADC characteristic of cytotoxic response
is due to major cell loss, reduced cell density, and widening
of the extracellular space (ECS)—all resulting in water
liberation [19].
Using DW-MRI following TOOKAD-PDT of human pros-
tate adenocarcinoma xenografts, we demonstrate that re-
sponse to treatment, similar to other cancer therapies, is
characterized by an increase in ADC as soon as 2 days after
PDT. However, quite surprisingly, prior to that rise in ADC
and as early as 7 hours after PDT, a significant decrease
in ADC was observed. In order to examine the role of the
nonvascular compartment in early response to TOOKAD-
PDT, we used in vitromulticellular spheroids as an avascular
tumor model [21–23] and also observed a PDT-induced
decrease in ADC. To the best of our knowledge, a decline
in ADC in response to PDT in tumors has not been previously
reported. The results obtained in this study suggest a unique
ADC-dependent pattern of tumor response to TOOKAD-PDT
that could eventually be useful in early clinical monitoring of
response to therapy.
Materials and Methods
Photosensitizer
For animals TOOKAD (2.5 mg/ml) was administered in
5% Cremophor El–based formulation (NEGMA-LERADS,
Toussus-Le-Noble, France).
For spheroids TOOKAD was prepared as previously de-
scribed [24]. Stock solution (1 mM) was prepared with
dimethyl sulfoxide (DMSO) and further diluted with culture
medium to 10 mM of 1% DMSO.
Tumor Xenograft Studies
Animal and tumor model Cell suspension of human pros-
tate adenocarcinoma (Weizmann Institute Sheba Hospital
prostate cancer 14, WISH-PC14) originating from a recurrent
tumor of a postdefinitive radiation therapy patient was pre-
pared as described previously [25]. Cells were mixed with
Matrigel (1:1, vol/vol) (Becton Dickinson, Bedford, MA) and
subcutaneously injected in the hind limb of CD-1 male nude
mice (mice weight 28–32 g, 10  106 cells/mouse).
All animal experiments were approved by the Weizmann
Institute Institutional Animal Care and Use Committee.
PDT protocol for animals PDT was performed on subcu-
taneous xenografts 7 to 12 mm in diameter (tumor reached
treatment size in 4–5 weeks). Mice were anesthesized with
intraperitoneal injection of 75 mg/kg Ketaset (ketamine; Fort
Dodge Laboratories, Fort Dodge, IA) and 3 mg/kg XYL-M
(xylazine; VMD, Arendonk, Belgium) followed by subcutane-
ous addition of about 30% of the initial dose in order to
prolong anesthesia. Anesthesized mice were intravenously
injected with 10 mg/kg TOOKAD and the tumor was im-
mediately illuminated for 10 minutes (108 J/cm2) using a
763-nm, 1-W diode laser (Ceramoptec, Bonn, Germany).
The light spot diameter included a 2 to 3 mm margin around
the tumor. Tumor response was recorded by DW-MRI and
was additionally examined by direct tumor documenta-
tion (photography and volume determination), histolo-
gical techniques, and immunohistochemical techniques.
Serum PSA levels were also determined. Tumor volume
(mm3) was determined by caliper measurement using the
formula: length  width  depth  0.5236 [26] and verified
by MRI (see below). All therapeutic results were obtained
following a single treatment session.
Controls: light control (illumination [108 J/cm2] only) and
dark control (TOOKAD [10 mg/kg] only).
Diffusion MRI of animals Animals were studied in a hori-
zontal 4.7 T Biospec spectrometer (Bruker, Germany) using
an actively radiofrequency (RF)–decoupled 1.5 cm surface
coil (for RF receiving) and a whole-body transmission coil.
Pulsed gradient spin-echo MRI protocol was applied on axial
slices before and after PDT. Anesthetized mice were placed
in a homebuilt half-cylindrical Perspex cradle that allowed
stable positioning of the mouse, such that the tumor was
located on top of the surface coil center. Prior to DW-MRI
scans, axial and coronal scout images were obtained to
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determine position, extent, and size of the tumor. ADC was
measured along a single direction, assuming that water
diffusion in the tumor is isotropic as in other prostate xeno-
grafts in mice [13,20]. DW-MRI scans were performed with a
diffusion gradient linearly incremented in the range of 0 to
150 mT/m with D = 35 milliseconds; d = 3 milliseconds,
yielding four b values: 6.9, 93.9, 290.4, and 596.4 sec/mm2;
time to repetition (TR) = 2000 milliseconds; time to echo
(TE) = 47.7 milliseconds, with two average repetitions;
matrix dimensions = 128  128; FOV = 3.5 cm; slice thick-
ness = 1 mm; number of slices (covering entire tumor
volume) = 5 or 7, depending on tumor size; total time = 34
minutes. Mice were covered with a recirculating water-filled
heating pad to maintain core body temperature at 37jC
during the course of MRI experiments.
Each animal underwent MRI examination prior to treat-
ment and at indicated time points (7, 24, and 48 hours)
posttreatment with further monitoring of tumor elimination
(up to 15–30 days) or histological examination of tumor
response.
Determination of PSA Serum PSA levels before and at
indicated time points after PDT were determined on serum
samples using two chemiluminescent immunometric assays
(LKPS1 and LKUP1 PSA kits, Immulite; Diagnostic Products
Corp., Los Angeles, CA).
Spheroid Model Studies
Spheroid culture Hepa-1 (murine hepatoma-1) [27] sphe-
roids were cultured in Dulbecco’s modified Eagle’s medium
(DMEM) containing 25 mM HEPES, pH 7.4, 10% heat-
inactivated fetal calf serum (Biological Industries, Bet
Haemek, Israel), glutamine (2 mM), penicillin (0.06 mg/ml),
and streptomycin (0.1 mg/ml) to the size of f1 mm in
diameter, as described earlier [27].
PDT protocol for spheroids Spheroids were preincubated
for 4 hours in the dark with 10 mM TOOKAD, washed with
fresh culture medium to remove unbound sensitizer, and
illuminated for 10 minutes at room temperature through
the bottom of a culture Petri dish (650 nm < k >800 nm,
18 J/cm2). Photocytotoxicity was analyzed by fluorescent
staining with propidium iodide (PI) (Sigma Chemical Co., St.
Louis, MO). Briefly, spheroids were incubated with 10 mg/ml
PI for 30 minutes, washed twice with fresh medium, and
visualized by fluorescent microscopy (Optiphot2 fluorescent
microscope; Nikon, Tokyo, Japan) equipped with a CCD
camera (DVC Inc., Austin, TX). In the PDT group, only
PDT- responsive spheroids in which the viable rim was
positively stained were scanned by MRI.
Controls: untreated (no light, no TOOKAD); light control
(illuminated only, in medium with 1% DMSO); dark control
(TOOKAD incubation in the dark [10 mM, 4 hours], without
illumination); and PI only (10 mg/ml, 30 minutes).
Diffusion MRI of spheroids Studies were performed on a
vertical-bore 9.4 T DMX 400 MHz spectrometer (Bruker)
equipped with an actively shielded NMR microscopy unit.
Pulsed gradient spin-echo MRI protocol was applied on axial
slices of spheroids before and 20 hours after PDT. DW-MRI
scans were performed with a diffusion gradient incremented
linearly in the range of 0 to 190 mT/m with D = 16.7 milli-
seconds, d = 6 milliseconds, yielding four b values: 182.6,
604.6, 1328.2, and 2353.3 sec/mm2; TR = 2000 millisec-
onds; TE = 31.5 milliseconds, with two averaging repetitions;
matrix dimensions = 128  128; FOV = 0.5 cm; slice thick-
ness = 0.3 mm; single slice per scan; total time = 34 minutes;
and temperature = 37jC.
MRI data analysis
MRI data were analyzed on an Indigo-2 /02 workstation
(Silicon Graphics, Mountain View, CA) using Paravision soft-
ware (Bruker) andMATLAB (TheMathWork, Inc., Natik, MA).
The MR signal was fitted to a monoexponential decay:
S / S0 = exp[b*ADC], where S and S0 are water signal
intensities in the presence and absence of diffusion-sensi-
tizing gradients, respectively, and b is the diffusion weighting
factor comprised of d (duration of gradient pulse), D (sepa-
ration of gradient pulses), g (gyromagnetic ratio), and G
(gradient pulse strength), and also includes cross terms
between imaging gradients and diffusion-sensitizing gra-
dients [28]. Diffusion maps for each slice were generated,
yielding ADC values for each pixel, and further analyzed by
means of region-of-interest (ROI) measurements (taken
from all slices where tumor is clearly identified) and were
assembled to yield the mean ADC of the tumor. ADC histo-
grams of the tumors at indicated time points after PDT were
generated from ROIs combined across slices.
As only a single slice can be measured in spheroids, the
mean ADC of a number of spheroids in the experimental
group was calculated. Mean ADCs of tumor/spheroids at
each time point were subjected to two-tailed t-test.
Histology
Tumors (harvested from euthanized mice) were fixed
and prepared for histological examination as described
earlier [6].
Immunohistochemistry
Paraffin-embedded histological sections of tumors/sphe-
roids were immunostained for the presence of PDT-induced
LPO product, 4-hydroxy-2-nonenal (HNE), as described
earlier [6].
Results
The Response of Human WISH-PC14 Xenografts to
TOOKAD-Based PDT
Tumor-bearing mice received either one treatment ses-
sion of TOOKAD-PDT, TOOKAD alone (dark control), or
illumination alone (light control). In PDT-treated tumors, local
inflammatory response was observed within hours after
treatment, developing into visible necrosis by 24 to 48 hours.
Necrosis appeared as a dark crust on the skin by 48 to 72
hours and reached its maximal size by 4 to 6 days. The
healing process culminated with complete tissue remodeling
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by 15 to 30 days (Figure 1A). Out of 19 treated animals,
14 (74%) exhibited complete necrosis (at 48–72 hours) and
five exhibited partial or no response. From the responding
group, two were sacrificed for histological examination
and three died from unknown reasons. The remaining nine
mice were followed up to complete recovery for 30 days.
Dark (n = 4) and light (n = 4) (Figure 1B) controls were
unaffected and continued to grow. The mice were euthan-
ized 15 to 30 days posttreatment to avoid excessive tumor
burden (z 2000 mm3).
In a separate experiment, tumor response to PDT was
also evaluated by examination of serum PSA (Figure 1C). A
significant 50% decrease in PSA was detected already
7 hours after PDT, which continued to decline, reaching
undetectable levels (< 1%) by 1 week after treatment. In
the light control (LC), PSA levels continued to increase
rapidly. Initial PSA level of all xenografts tested (n = 13)
was 15 ± 12 SD ng/ml on average. TOOKAD-PDT of WISH-
PC14 xenografts proved efficient by three parameters:
tumor necrosis (2–3 days), tumor shrinkage and eradication
(2–3 weeks), and a significant decline of serum PSA levels
that could be detected within hours (z 7 hours).
Monitoring the Early Response of Human WISH-PC14
Xenografts to TOOKAD-Based PDT by DW-MRI
Based on the successful eradication of human WISH-
PC14 xenografts by the above PDT protocol, we further
examined the response to treatment during the first 48 hours
using DW-MRI. Following PDT of the tumor (Figure 2A,
PDT ), mean ADC values of untreated tumors (T) (time 0,
6.99 ± 0.64  10-4 SD mm2/sec, n = 6) declined by f25%
(5.28 ± 0.74  10-4 mm2/sec, P = .34  10-4, n = 6) 7 hours
Figure 1. The response of human WISH-PC14 xenografts to TOOKAD-based PDT. Direct examination of tumor response to TOOKAD-based PDT (10 mg/kg,
108 J/cm2 for 10 minutes) before (0) and up to 30 days posttreatment (A). Tumor growth curves starting from day of treatment (day 0) are presented (B). The
number of mice per PDT group: n = 9; light control (LC) and dark control (DC) groups: n = 4 each. Normalized (%) PSA levels in PDT and LC before and at indicated
times after treatment are presented up to 14 days (C). Number of animals examined at each time point is indicated. Bars represent mean ± SD.
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Figure 2. Monitoring the early response of human WISH-PC14 xenografts to TOOKAD-based PDT by DW-MRI. Diffusion maps (A) of axial slices were generated,
yielding ADC of each pixel of PDT-treated tumors (PDT) light control (LC) and dark control (DC) at indicated times before (0) and after treatment (7, 24, and
48 hours). For each time point, three consecutive axial slices are presented. Tumor (T), edema (E), and schematic illustration of ROI selection in tumor are
indicated. Arrows indicate direction of illumination. Two enlarged representative slices before and 7 hours after treatment are also presented (lower box). DW
images were evaluated by means of ROI measurements of the tumor area and ADC of tumors for PDT (n = 6), LC (n = 3), and DC (n = 3) was calculated and
presented as bar graphs. Bars represent mean ± SD. Mean ADCs of each time point were subjected to paired two-tailed t-test, *, **, *** Significantly different from
each other (p < 0.005). ADC histograms (B) were derived from ROIs of tumors after PDT (n = 3) and represent the distribution of ADC values at the times of
measurement post-PDT. Results obtained in the representative tumor (A) are shown.
Figure 3. Monitoring the response of human WISH-PC14 xenografts to TOOKAD-based PDT by histological and immunohistochemical examination. Tumors from
light control (LC; A), dark control (DC; B), and 7, 24, and 48 hours post-PDT (C, D, and E, respectively) were fixed and stained with hematoxylin and eosin (n = 2 for
each one presented in the figure). The same tumors from LC (F), DC (G), and 7, 24, and 48 hours post-PDT (H, I, and J, respectively) were also immunostained for
LPO by anti –HNE antibodies. Scale bar = 50 m.
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post-PDT. At 24 hours, mean ADC values increased (6.17 ±
1.00  10-4 mm2/sec, P = .251, n = 6) to below the initial
untreated levels. This increase is more apparent at the
tumor rim. By 48 hours post-PDT, ADCwas further increased
(12.56 ± 2.39  10-4 mm2/sec, P = .004, n = 6) up to 1.8-fold
over values of untreated tumors, correlating with the devel-
opment of hemorrhagic necrosis in the tumor (all t-tests
presented above are relative to untreated).
In contrast to observations in the tumor, massive edema
(E) associated with an increase in diffusion was observed
in the surrounding illuminated tissue 7 hours after PDT. The
enhanced contrast at the tumor boundaries emphasized
tumor response to PDT. The changes in ADC in the tumor
were all light- and sensitizer-dependent and no significant
changes in ADCwere observed in the light (n = 3) (Figure 2A,
LC ) or dark (n = 3) (Figure 2A, DC ) controls. ADC histo-
grams of PDT-treated tumors (n = 3) were generated and
exhibited high pattern similarity. One such analysis
(corresponding to ADC maps in Figure 2A, PDT ) is pre-
sented (Figure 2B ). Interestingly, this revealed that the
biphasic change in tumor ADC values post-PDT was asso-
ciated with respective narrowing (7 hours) and subsequent
broadening (24 and 48 hours) of the ADC value distribution.
These results demonstrate for the first time that treatment
of a human prostate xenograft with TOOKAD-PDT induces a
unique and significant transient decline in ADC concomitant
with a decline in PSA (Figure 1).
Monitoring the Response of Human WISH-PC14 Xenografts
to TOOKAD-Based PDT by Histological and Immunohisto-
chemical Examination
To validate the direct/clinical and DW-MRI observations,
the response to treatment during the first 48 hours was
histologically examined. In light (Figure 3A), dark (Figure 3B ),
and untreated (not shown) controls, live neoplastic cells
were visible, exhibiting marked atypia. In addition, multifo-
cal cyst formation and mild multifocal lymphoplasmacystic
infiltration surrounding the mass were evident. At 7 hours
post-PDT (Figure 3C ), neoplastic cells were viable, although
degenerative changes in the form of cytoplasmic vacuo-
lation were observed. There was separation and smudging
of dermal collagen consistent with edema (Figure 3C,
insert; tumor [T] and traces consistent with edema in skin
[S] are indicated). After 24 hours (Figure 3D ), there were
also multifocal hemorrhages (He) and necrotic/apoptotic
cells (Nc) in the periphery of the tumor. The neoplastic
cords were widely separated from each other, consistent
with the presence of protein-poor edema (Figure 3D,
insert ). There was widespread necrosis of the overlying
skin with relative sparing of the interfollicular epidermis. By
48 hours (Figure 3E ), there was massive necrosis of the
tumor with few peripheral hemorrhages and, as at 24
hours, widespread necrosis of the overlying skin.
Response to TOOKAD-PDT was also monitored by HNE
staining for LPO (as a PDT response marker). Although
negative HNE staining in all controls (Figure 3, F and G)
indicated no traces of LPO, positive HNE staining (brown)
throughout the tumor mass at 7, 24, and 48 hours post-PDT
(Figure 3, H–J, respectively) indicated the presence of LPO.
These results confirmed tumor damage progression and
PDT-associated LPO in the illuminated tumor of a TOOKAD-
treated mouse.
Monitoring the Response of Hepa-1 Spheroids to TOOKAD-
Based PDT by DW-MRI
In order to examine the contribution of the tumor’s non-
vascular compartment to the observed change in PDT-in-
duced ADC, we conducted a PDT experiment in multicellular
spheroids simulating avascular tumors. AsWISH-PC14 does
not form spheroids in vitro, we used Hepa-1 cells to generate
spheroids. The mean water ADC in an ROI containing
the viable rim of untreated spheroids (Figure 4A) was
5.73  10-4 ± 0.23 SDmm2/sec, whereas PDT-treated sphe-
roids (Figure 4B ) had af23% lower average ADC value of
4.42  10-4 ± 0.27mm2/sec (P = .003, two-tailed t-test). Data
represent three independent experiments, with four to five
spheroids per experimental group. Average ADC value of
light, dark, and PI controls did not significantly differ from
untreated control (data not shown). TOOKAD-induced
photocytotoxicity was determined for all spheroids
scanned by MRI using PI (prior to MRI examination). In
control spheroids, there was no PI staining in the viable
rim; however, PI staining was detected in cells located in the
central hypoxic region. This region contains the necrotic core
and the surrounding quiescent cells characterized by de-
creased pO2 [21] (Figure 4C ). After PDT, only spheroids that
stained positively with PI in the former viable rim (FVR) were
studied by MRI (Figure 4D). Consistent with PDT-treated
tumors, histological sections of untreated spheroids did
not stain for HNE in the viable rim (Figure 4E ), whereas
the rim region of PDT-treated spheroids stained positive
for HNE (Figure 4F ). Although there is some HNE staining
in the hypoxic area, staining in the FVR appears only after
PDT. It could therefore be concluded that the decline of
ADC can also be induced in vitro in an avascular cell
spheroid model.
Discussion
The major finding of this study is the unique temporal
biphasic change in ADC observed in treated tumors within
24 hours after PDT with TOOKAD. This phenomenon is
suggested as an early indicator of tumor response to this
treatment. Furthermore, it is suggested that this transient
response correlates with the desired treatment outcome
(necrosis 48 hours post-PDT) culminating in tumor eradica-
tion. The PDT protocol used had an overall success rate of
74% using tumor necrosis as endpoint. The necrotic process
developing over the first 24 to 48 hours (Figure 1A) led to
flattening of the treated tumors byf day 5, yielding complete
tissue remodeling by 30 days after PDT in 9 of 14 mice
(Figure 1B). Temporal changes in blood supply to various
tumor regions can result in heterogeneous distribution of the
sensitizer and, hence, account for incomplete response to
PDT. A significant reduction in PSA levels was already
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apparent by 7 hours (Figure 1C ), in agreement with other
response parameters (Figure 2, ADC; Figure 3, LPO ) and
subsequent treatment outcome (Figure 1, A and B ). These
data support previous findings of our laboratory showing that
a single treatment session of TOOKAD-PDT can success-
fully eradicate subcutaneous SCCP xenografts as well as
orthotopic and intraosseous tumors in CD-1 nude mice [6].
PDT is known as a minimally invasive treatment that has
profound and rapid effects on the treated tissue within
minutes of illumination, inducing severe hemodynamic dis-
turbances with consequent hypoxia [5,11,29]. It was there-
fore reasonable to correlate changes in tissue consistency
developing within hours after treatment with the tracked
changes in DW-MRI.
Conventional cancer treatment modalities like chemo-
therapy or radiotherapy require repetitive treatment sessions
over periods of weeks to months. Consequently, response to
treatment is slow and estimation of success by palpation or
imaging (X-ray, ultrasonography, computed tomography,
and MRI) as well as tumor markers may require substantial
time elapse before detectable changes in size or contrast
can be observed. In contrast, PDT practiced in ambulatory
clinics or hospitals is short (approximately an hour) and
estimation of response to treatment monitored within the
day of treatment would be of great benefit. As demonstrated
in this study, tumor necrosis by direct/clinical (Figure 1) and
histological (Figure 3) parameters is consistent with an
increase in ADC at the tumor rim (24 hours) covering the
Figure 4.Monitoring the response of Hepa-1 spheroids to TOOKAD-based PDT by DW-MRI. Hepa-1 spheroids were MRI-scanned before and 20 hours post-PDT.
Diffusion maps of untreated controls (A) and PDT-treated spheroids (B) were generated. PI stainings of untreated controls (C) and PDT-treated spheroids (D)
are shown. Anti –HNE stainings of untreated control (E) and PDT-treated (F) spheroid are shown. NC, necrotic core; VR, viable rim; FVR, former viable rim;
SP, spheroid.
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entire tumor by 48 hours post-PDT (Figure 2, A and B). Of
great importance is the observation that at 7 hours post-PDT,
the decrease in tumor ADC (Figure 2, A and B ) was
coincidental with an increase in ADC in the surrounding
normal tissue (due to edema) (Figure 2A). This concomitant
inverse response observed on the tumor boundary enhances
local MR contrast, demonstrating the differential and selec-
tive response of the two tissues to PDT. These PDT-induced
changes correlate well with previous finding that showed
tumor response by hemodynamic parameters [5] within
minutes of illumination and by LPO within hours to days [6]
(Figure 3). Minimal edema due to laser illumination is seen in
light control (Figure 2A, LC ) and is totally absent in dark
control (Figure 2A, DC ). Changes in ADC value distribution
as shown in the histograms (Figure 2B ) may represent an
ADC signature of tumor response to TOOKAD-PDT, the
basis of which has yet to be elucidated. We wish to state
that although desirable in this study, animal imaging at a time
interval shorter than 7 hours post-PDT was prohibited by the
well being of the mice following anesthesia, but may be
possible in humans.
The decline in ADC following TOOKAD-PDT is unique
with respect to pattern and time of appearance compared
with increase in ADC observed following most conventional
therapies. In oncology and preclinical cancer models, early
tumor response (characterized by high ADC) is usually
referred to a minimum of 2 days after cytotoxic treatment,
often prior to significant decrease in tumor size [30]. For
example, an increase in ADCwas described for the response
of LnCaP human prostate adenocarcinoma xenografts to
chemotherapy with docetaxel 2 days after treatment [13]. An
increase in ADC of orthotopic rat brain 9L glioma tumors
was also observed 2 days after 1,3-bis (2-chloroethyl)-1-
nitrosourea (BCNU) treatment [31].
Increase in tumor ADC and necrotic response to therapy
were shown to develop simultaneously. The histological
characteristics of necrosis include increased ECS, reduced
cellularity, and liberation of water from cells [19]. Increase in
ADC is common for tumor response to cytotoxic treatments
including a single report on ALA-PDT [32]. Decreased diffu-
sivity has been described in normal brain tissues in associ-
ation with acute cerebral ischemia [19] and following
porphyrin-based Photofrin II-PDT in normal brain, where a
biphasic temporal response pattern similar to the one de-
scribed here was observed [33].
A biphasic temporal ADC response pattern was also
observed after convection-enhanced Taxol delivery in brain
tumor patients [34]. To the best of our knowledge, a
decrease in ADC as a marker for early response to cyto-
toxic treatment of normal/tumorigenic tissue outside the
brain has not been reported. ADC decrease is detected at
later times (weeks) after therapy usually due to local
regrowth [31] or fibrosis [35]. It is indeed possible that in
the case of local tumor regrowth after TOOKAD-PDT, a
decrease in ADC to pretreatment values may also be
observed. Reduction in ADC of water in acute cerebral
ischemia was originally attributed to a reduction of ECS
volume fraction [19], whereas the decreased tumor ADC in
our model at 7 hours was not associated with reduction of
ECS (Figure 3C ). However, the connection between ECS
and ADC changes can only partially explain the observed
changes in water diffusion associated with acute ischemia
in vivo [19]. Decrease in water ADC could also result from
alterations in intracellular compartmentalization, such
as cytoplasmic vacuolation observed 7 hours post-PDT
(Figure 3C ), or changes in permeability of cell membranes
to water and ions [36].
Ischemia and deoxygenation are also causes of tissue
damage by Photofrin-PDT [37], bacteriochlorophyll serine-
PDT [29], and TOOKAD-PDT [5]. Similar to bacteriochlo-
rophyll-based PDT [5,7,11,29], the anti– tumor activity of
combretastatin A4 prodrug was also antivascular and was
shown to induce a significant decrease in perfusion and
oxygenation of a murine sarcoma tumor immediately after
treatment [38]. In the TOOKAD-PDT xenografts, ADC that
was measured with relatively low b values (7–596 sec/mm2)
probably also reflects the antivascular effect that TOOKAD-
PDT has on blood microcirculation in the tumor capillary
network [39]. Indeed, a correlation between low oxygena-
tion levels (caused by vascular occlusion) and low ADC in
certain tumor regions was reported [40], but although
combretastatin A4 induced a decline in oxygenation, it
was not associated with a decrease in tumor ADC [38].
In contrast, TOOKAD-PDT suggests an association be-
tween a decline in oxygenation posttreatment [5] and a
decrease in tumor ADC as reported here. We thus postu-
late that an additional common denominator between PDT
and cerebral ischemia attributes to the decrease in ADC
observed.
LPO is a response marker for PDT with TOOKAD
(Figure 3) [5,6] and porphyrin derivatives [41], and has
been described in the process of cerebral ischemia [42] but
not in combretastatin action. Although LPO is initiated by
photosensitized ROS, the dominant part of necrotic tumor
damage in the case of TOOKAD-PDT spreads the tumor
after illumination presumably by free radical chain reactions
that are in progress by 7 hours after treatment (Figure 3H ).
We suggest here that the decrease in ADC could result
from endogenous generation of toxic LPO products derived
from membrane lipid modifications. These may include cy-
totoxic aldehydes and peroxides that either cross-link or
inactivate enzymes and transporters, leading to general
metabolic arrest (e.g., depletion of ATP) [43], thereby block-
ing active ion and water transport. As a result, a transient
decline in ADC may develop prior to cell lysis and necrosis,
leading to water liberation and increase in ADC.
Because TOOKAD-PDT is an anti–vascular treatment
where the target tumor cells are destroyed secondary to
photodestruction of the tumor vasculature, it was important
to establish the contribution of the nonvascular compartment
of the tumor to the overall initial decrease in ADC. In order to
examine this issue, we resorted to a cell spheroid as a model
of an avascular tumor.
The experimental results obtained (Figure 4) seem to
validate a decrease in ADC induced by TOOKAD-PDT in
this model. Furthermore, these results support the dominant
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role of the nonvascular compartment in the ADC decline
during early stages of tumor response to PDT. These results
are also consistent with the suggested role of LPO in the
mechanism of ADC decline (Figure 4F ). PI penetration into
the cells of the spheroid FVR is passive yet PDT-dependent
(Figure 4D). Thus, the observed changes in ADC are con-
comitant with an initial change in cell membrane permeability
(permitting PI penetration) and do not involve hemodynamic
or inflammatory processes. In the spheroid model, ADC was
measured with relatively high b values (and other compara-
ble parameters as previously reported) [22] and thus weight-
ed heavier by the intracellular compartment. Nevertheless, if
the decrease in ADC also represents a change in ADC of
extracellular water, it is possible that LPO products departing
from cell membranes into the ECS (still prior to necrosis)
might increase tortuosity, thereby causing a transient de-
crease in ADC.
It should be noted that the ADC decrease in spheroids
was determined only at 20 hours post-PDT, yet the prin-
cipal observation and conclusion that PDT induces an
initial rapid decline in ADC are essentially identical. The
sustained low ADC in the in vitro model may relate to
differences between models. In addition, the lack of de-
creased ADC at 20 hours in vivo differs from the in vitro
model, suggesting a possible masking of the decline in
ADC by a subsequent necrosis that results in increased
ADC. This is either delayed in vitro or perhaps requires
hemodynamic or inflammatory contributions that are absent
in the spheroid model.
In summary, this study suggests that the rapid decline
in ADC in human prostate adenocarcinoma xenografts
can serve as an early response marker for success-
ful TOOKAD-PDT apparent within 7 hours of treatment.
TOOKAD-PDT of localized PC (currently in clinical trials) is
enabled by short illumination using fiber optic light delivery
immediately after intravenous injection of TOOKAD. It is
important to provide the means for rapid assessment of
tumor response and prediction of treatment outcome. The
possible need for adjuvant or alternative treatment may
thus be assessed within hours after treatment. Currently,
the evaluation of treatment outcome of other minimally
invasive anti–PC treatments (like brachytherapy) is based
on PSA levels, dictating long time follow-up intervals as
frequently observed when a more progressive disease is
already attained. Although we observed a 50% drop in PSA
levels as early as 7 hours after treatment in the human
xenograft model, PSA levels in humans are not expected to
change as fast, due to normal basal PSA secretion and a
longer half life. In the case of other minimally invasive
treatments (e.g., cryotherapy) that elicit rapid tumor re-
sponse, the advantages of using MRI for analyzing the full
extent of treatment during and after therapy are clear [44]
and similar to those desired in PDT. The present study
suggests the application of DW-MRI as a noninvasive rapid
methodology for monitoring tumor response within a few
hours after PDT. We believe that this technique may
provide clinical advantages by allowing evaluation of tumor
response on the day of treatment.
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